Imitab 100 mg (Tablet)

Unit Price: ৳ 100.00 (3 x 10: ৳ 3,000.00)
Strip Price: ৳ 1,000.00

Medicine Details

Category Details
Generic Imatinib mesylate
Company Eskayef pharmaceuticals ltd
Also available as
Imitab 400 mg tablet

Indications

  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase
  • Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy
  • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
  • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
  • Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements
  • Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown
  • Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR a fusion kinase
  • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans
  • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
  • Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST

Pharmacology

  • Small molecule protein-tyrosine kinase inhibitor
  • Inhibits Bcr-Abl tyrosine kinase (TK) and other receptor TKs (Kit, DDR1, DDR2, CSF-1R, PDGFR-alpha, PDGFR-beta)
  • Potent inhibitor of cellular events mediated by activation of receptor kinases

Dosage & Administration

  • 400 mg/day for adults with Ph+ CML CP
  • 600 mg/day for adults with Ph+ CML AP or BC
  • 340 mg/m2/day for pediatrics with Ph+ CML CP
  • 600 mg/day for adults with Ph+ ALL
  • 340 mg/m2/day for pediatrics with Ph+ ALL
  • 400 mg/day for adults with MDS/MPD
  • 100 mg/day or 400 mg/day for adults with ASM
  • 100 mg/day or 400 mg/day for adults with HES/CEL
  • 800 mg/day for adults with DFSP
  • 400 mg/day for adults with metastatic and/or unresectable GIST
  • 400 mg/day for adjuvant treatment of adults with GIST
  • Doses to be taken with a meal and a large glass of water

Interaction

  • Agents Inducing CYP3A Metabolism may reduce total exposure of imatinib; consider alternative agents
  • Agents Inhibiting CYP3A Metabolism may result in a significant imatinib exposure increase; avoid grapefruit juice
  • Interactions with Drugs Metabolized by CYP3A4: Imitab will increase plasma concentration of CYP3A4 metabolized drugs
  • Use caution when administering Imitab with CYP2D6 substrates that have a narrow therapeutic window

Side Effects

  • Fluid Retention and Edema
  • Hematologic Toxicity
  • Congestive Heart Failure and Left Ventricular Dysfunction
  • Hepatotoxicity
  • Hemorrhage
  • Gastrointestinal Disorders
  • Hypothyroidism
  • Growth Retardation in Children and Adolescents
  • Tumor Lysis Syndrome
  • Impairments Related to Driving and Using Machinery
  • Renal Toxicity

Pregnancy & Lactation

  • Women of childbearing potential must use effective contraception during treatment and for at least 15 days after stopping treatment with Imatinib
  • Imatinib should not be used during pregnancy unless clearly necessary
  • Avoid breast-feeding during treatment and for at least 15 days after stopping treatment with Imatinib

Precautions & Warnings

  • Edema and severe fluid retention
  • Cytopenias, particularly anemia, neutropenia, and thrombocytopenia
  • Severe congestive heart failure and left ventricular dysfunction
  • Severe hepatotoxicity, including fatalities may occur
  • Grade 3/4 hemorrhage
  • Bullous dermatologic reactions
  • Fetal harm can occur when administered to a pregnant woman
  • Growth retardation occurring in children and pre-adolescents
  • Tumor Lysis Syndrome
  • Renal Toxicity

Overdose Effects

  • Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms
  • Thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite
  • Weakness, myalgia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain

Therapeutic Class

  • Targeted Cancer Therapy
  • Tyrosine Kinase Inhibitor

Storage Conditions

  • Store below 30°C
  • In a cool and dry place
  • Keep away from light
  • Keep out of the reach of children

Related Brands